These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 27532651)
41. [Stroke Associated with Atrial Fibrillation and Novel Oral Anticoagulants (NOACs)]. Ieko M Rinsho Byori; 2014 Oct; 62(10):948-57. PubMed ID: 27526540 [TBL] [Abstract][Full Text] [Related]
42. New oral anticoagulants for patients with nonvalvular atrial fibrillation. Holden A; Azimi N; Forest CP JAAPA; 2015 Nov; 28(11):28-34. PubMed ID: 26501575 [TBL] [Abstract][Full Text] [Related]
43. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR; Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971 [TBL] [Abstract][Full Text] [Related]
45. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790 [TBL] [Abstract][Full Text] [Related]
46. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? Arepally GM; Ortel TL Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651 [TBL] [Abstract][Full Text] [Related]
47. Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial. Senoo K; Lip GY Stroke; 2016 Feb; 47(2):523-6. PubMed ID: 26628383 [TBL] [Abstract][Full Text] [Related]
48. Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: what are the obstacles? Wong CW Hong Kong Med J; 2016 Dec; 22(6):608-15. PubMed ID: 27920399 [TBL] [Abstract][Full Text] [Related]
49. Rivaroxaban: can we trust the evidence? Cohen D BMJ; 2016 Feb; 352():i575. PubMed ID: 26843102 [No Abstract] [Full Text] [Related]
50. Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. Stewart RA Curr Opin Cardiol; 2011 Jul; 26(4):294-9. PubMed ID: 21537165 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940 [TBL] [Abstract][Full Text] [Related]
52. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice. Barón-Esquivias G; Marín F; Sanmartín Fernandez M Expert Rev Cardiovasc Ther; 2017 May; 15(5):403-413. PubMed ID: 28319424 [TBL] [Abstract][Full Text] [Related]
53. Apixaban versus warfarin in atrial fibrillation. Vassiliou VS N Engl J Med; 2012 Jan; 366(1):88; author reply 89. PubMed ID: 22216849 [No Abstract] [Full Text] [Related]
54. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
55. PURLs: Direct oral anticoagulants or warfarin for A fib? Lyon C; Reed A; Prasad S J Fam Pract; 2017 Aug; 66(8):518-519. PubMed ID: 28783771 [TBL] [Abstract][Full Text] [Related]
56. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056 [TBL] [Abstract][Full Text] [Related]
57. Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR Circulation; 2016 Jul; 134(2):e7-8. PubMed ID: 27400902 [No Abstract] [Full Text] [Related]
58. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. Chen J; Zhuang X; Long M; Su C; Wang L J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517 [TBL] [Abstract][Full Text] [Related]
59. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Westenbrink BD; Alings M; Granger CB; Alexander JH; Lopes RD; Hylek EM; Thomas L; Wojdyla DM; Hanna M; Keltai M; Steg PG; De Caterina R; Wallentin L; van Gilst WH Am Heart J; 2017 Mar; 185():140-149. PubMed ID: 28267467 [TBL] [Abstract][Full Text] [Related]
60. Letter by Imprialos et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". Imprialos K; Boutari C; Stavropoulos K Circulation; 2016 Jul; 134(2):e5-6. PubMed ID: 27400901 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]